Cargando…

Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2

BACKGROUND: Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Fenioux, Charlotte, Allenbach, Yves, Vozy, Aurore, Salem, Joe-Élie, Maalouf, Georgina, Vieira, Matheus, Le Joncour, Alexandre, Benveniste, Olivier, Saadoun, David, Frère, Corinne, Campedel, Luca, Salem, Pierre, Gligorov, Joseph, Funck-Brentano, Christian, Cacoub, Patrice, Gougis, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société Française du Cancer. Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980139/
https://www.ncbi.nlm.nih.gov/pubmed/33966886
http://dx.doi.org/10.1016/j.bulcan.2021.03.004
Descripción
Sumario:BACKGROUND: Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer. METHODS: This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017). RESULTS: Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised. CONCLUSIONS: Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic.